Morbidity and mortality in schizophrenia

British Journal of Hospital Medicine

Volumn 72, Issue 11, 2011, Pages 628-630

  Lwin, A M ^a   Symeon, C ^b   Jan, F ^c   Sule, A ^d  

^a Psychiatry Core Trainee 2 in the South Essex Partnership Trust   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^c HERTFORDSHIRE PARTNERSHIP UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80955166847     PISSN: 17508460     EISSN: None     Source Type: Journal    
DOI: 10.12968/hmed.2011.72.11.628     Document Type: Review

References (29)

1. Dean CE, Thuras PD (2009) Mortality and tardive dyskinesia: longterm study using the US National Death Index. Br J Psychiatry 194: 360-4
2. Druss B, Bradford DW, Rosenheck RA, Radford MJ, Krumholz HM (2000) Mental disorders and use of cardiovascular procedures after myocardial infarction. JAMA 283: 506-11 (Pubitemid 30062867)
3. Eklund M, Hansson L (2007) Social network among people with persistent mental illness: Associations with sociodemographic, clinical and health-related factors. Int J Soc Psychiatry 53: 293-305 (Pubitemid 47034364)
4. Goldberg D, Jackson G (1992) Interface between primary care and specialist mental health care. Br J Gen Pract 42(360): 267-9
5. Goldberg EM, Morrison SL (1963) Schizophrenia and social class. Br J Psychiatry 109: 785-802
6. Green AI, Canuso CM, Brenner MJ et al (2003) Detection and management of comorbidity in patients with schizophrenia. Psychiatr Clin North Am 26: 115-39 (Pubitemid 36384351)
7. Hanssens L, De Hert M, Kalnicka D et al (2007) Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia. Int Clin Psychopharmacol 22: 43-9 (Pubitemid 44950767)
8. Hennekens C, Hennekens AR, Hollar D, Casey DE (2005) Schizophrenia and increased risks of cardiovascular disease. Am Heart J 150: 1115-21 (Pubitemid 41773510)
9. Jeste DV, Gladsjo JA, Lindamer LA, Lacro JP (1996) Medical comorbidity in schizophrenia. Schizophr Bull 22: 413-27
10. Jones D, Macias C, Barreira PJ et al (2004) Prevalence, severity, and co-occurrence of chronic physical health problems of persons with serious mental illness. Psychiatr Serv 55: 1250-7 (Pubitemid 39441587)
11. Kelly C, McCreadie R (2000) Cigarette smoking and schizophrenia. Adv Psychiatr Treat 6: 327-31
12. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH (2000) Smoking and mental illness: A populationbased prevalence study. JAMA 284: 2606-10
13. Lopez AD, Murray CJ (1998) Global mortality, disability and the contribution of risk factors: the Global Burden of Disease Study. Natur Med 4: 1241-3
14. Meltzer H, Alphs L, Green AI et al (2003) Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (Intersept). Arch Gen Psychiatry 60: 82-91 (Pubitemid 36070868)
15. Mohamed S, Paulsen JS, O'Leary D, Arndt S, Andreasen N (1999) Generalized cognitive deficits in schizophrenia: A study of firstepisode patients. Arch Gen Psychiatry 56: 749-54 (Pubitemid 29357737)
16. National Institute for Health and Clinical Excellence (2009) Core interventions in the treatment and management of schizophrenia in primary and secondary care. guidance.nice.org.uk/CG82 (accessed 11 May 2011)
17. Osborn DP, Levy G, Nazareth I, Petersen I, Islam A, King MB (2007) Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database. Arch Gen Psychiatry 64: 242-9 (Pubitemid 46220782)
18. Parker C, Coupland C, Hippisley-Cox J (2010) Antipsychotic drugs and risk of venous thromboembolism: nested case-control study. BMJ 341: c4245
19. Parks J, Svendsen D, Singer P et al (2006) Morbidity and Mortality in people with serious mental illness. National Association of State Mental Health Program Directors, Medical Directors Council, Alexandria Virginia
20. Regier DA, Farmer ME, Rae DS et al (1990) Comorbidity of mental disorders with alcohol and other drug abuse: Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 264: 2511-18
21. Ryan MC, Collins P, Thakore JH (2003) Impaired fasting glucose tolerance in first-episode, drug-naïve patients with schizophrenia. Am J Psychiatry 160: 284-9 (Pubitemid 41110453)
22. Saha S, Chant D, McGrath J (2007) A systematic review of mortality in schizophrenia: Is the differential mortality gap worsening over time? Arch Gen Psychiatry 64: 1123-31 (Pubitemid 47529346)
23. Strom BL, Faich GA, Reynolds RF et al (2008) The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): design and baseline subject characteristics. J Clin Psychiatry 69: 114-21 (Pubitemid 351282004)
24. Tiihonen J, Walhbeck K, Lönnqvist J et al (2006) Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 333: 224-7 (Pubitemid 44406713)
25. Tiihonen J, Lönnqvist J, Wahlbeck K et al (2009) 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374: 620-7
26. Tran E, Rouillon F, Loze J et al (2009) Cancer mortality in patients with schizophrenia: An 11-year prospective cohort study. Cancer 115: 3555-62
27. Wang PS, Schneeweiss S, Avorn J et al (2005) Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 353(22): 2335-41 (Pubitemid 41713745)
28. Warburton D, Nicol CW, Bredin SD (2006) Health benefits of physical activity: the evidence. CMAJ 174: 801-9
29. Wright P, Sham PC, Gilvarry CM et al (1996) Autoimmune diseases in the pedigrees of schizophrenic and control subjects. Schizophr Res 20: 261-7 (Pubitemid 26232970)